Credence Genomics

Using Metagenomics
to battle Sepsis & AMR
Using the power of advanced technology and Big Data with machine learning to provide agnostic diagnostics.

At Credence Genomics our platform use the latest technology on our propriety platform to identify and treat sepsis while tackling AMR. A cost effective comprehensive solution which is fast and accurate.

Our Product

Bactfast®


22,000 bacteria in a single test using our propriety technology. Separation of contaminants commensal allow for increased accuracy. Recommended by by intensivists, infectious disease and microbiologists to tackle any type of bacterial identification in any sample.

Fungifast®

6,000 fungi in a single test using our propriety technology. Separation of contaminants commensal allow for increased accuracy. Used in both acute on chronic infections and long term chronic infections common in immunosuppressed individuals including transplant patients.

Virfast®

9000 viruses in a single test both DNA & RNA using our proprietary technology. Ideal for identifying any viral infection across multiple samples. Species and genotypic resolution available for every sample. The only product with the largest screening of viruses in a single test.

digitalABST®

Machine learning application to using the output from Bactfast to provide detailed antiobiotic resistance based on identified species.

The technique allows an ICU to very quickly get a comprehensive view of resistance and provide accurate treatment.

Case Studies

Detection of bacterial pathogens from clinical specimens using conventional microbial culture and 16S metagenomics: a comparative study

Metagenomics based results show a 91.8% concordance rate for culture positive specimens and 52.8% concordance rate with culture negative samples. 10.3% of specimens were also positive for fungal species which was not investigated by culture. Specificity and sensitivity for metagenomics analysis is 91.8 and 52.7% respectively.

Conclusion
16S based metagenomic identification of bacterial species within a clinical specimen is on par with conventional culture based techniques and when coupled with clinical information can lead to an accurate diagnostic tool for infectious disease diagnosis.

ICU care through NGS – Based identification of infectious agents: A comparative study
Utilization of Bactfast® in an ICU setting has shown advantages of NGS based pathogen identification in sepsis. A comprehensive clinical history with site and sample information is important for establishing possible commensal, and contaminant competition. Bactfast® results can be generated within 36 h, and provides data on the full spectrum of microbial species within a sample including anaerobic, and slow growing organisms. This is especially important in cases where culture, and other testing methods may have limited sensitivity or provide ambiguous results as Bactfast® will still provide information on pathogen by taking…
Bactfast®: A Rapid NGS diagnostic tool for Invasive Pneumococcal Disease (IPD) in pediatric ICU and surveillance of streptococcus pneumoniae serotypes for vaccine epidemiology

Total 120 patients were screened from Nov 2022 -May2023. A total of 46 were included in the study. All except 6 participants had received at least 1 dose of the pneumococcal vaccine. Streptococcus pneumoniae was detected in all study participants. Blood culture was negative in all participants except 2. After S. pneumoniae was detected, further analysis was carried out to identify serotypes present using sequenced data. Multiple serotype infection was reported in 52.1% of the patients, with serotype 14 and 4 showing the highest incidence. Non-vaccine serotypes 2, 6C, 11A, 33B and 35F was detected in only 28.2% of patients.

Client Testimonials

Our Technology

REPRODUCIBLE PATHOGEN IDENTIFICATION

Credence Genomics infectious disease platform is able to create a reproducible result of extremely high precision. Bactfast® & Fungifast® are CE-IVD certified. The multi sample platform is a comprehensive solution in ICU sepsis.

REPRODUCIBLE PATHOGEN IDENTIFICATION

Credence Genomics infectious disease platform is able to create a reproducible result of extremely high precision. Bactfast® & Fungifast® are CE-IVD certified. The multi sample platform is a comprehensive solution in ICU sepsis.

MULTI-LAYERED QUALITY CONTROL & VALIDATION

Quality and Validation steps across wet lab and dry lab is conducted over 5 steps. Integrated propriety protocols allow for comprehensive quality delivery in every sample.

BIG DATA & MACHINE LEARNING

Using machine learning and big data techniques Credence Genomics is able to accurately identify a pathogen while demarcating commensal & contaminant and provide precise antibiotic resistance .